Stay updated on Adjuvant Pembrolizumab in N2+ NSCLC Clinical Trial

Sign up to get notified when there's something new on the Adjuvant Pembrolizumab in N2+ NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Adjuvant Pembrolizumab in N2+ NSCLC Clinical Trial page

  1. Check
    5 days ago
    No Change Detected
  2. Check
    12 days ago
    Change Detected
    Summary
    Removed two cited references: a 2012 NEJM article on anti-PD-L1 therapy and a 1994 NEJM trial on preoperative chemotherapy plus surgery for NSCLC; this reduces the page’s bibliographic support and mentions of key sources.
    Difference
    1%
    Check dated 2025-10-19T16:37:47.000Z thumbnail image
  3. Check
    19 days ago
    Change Detected
    Summary
    Added a citation-style sentence about the safety and activity of an anti-PD-L1 antibody in advanced cancer (N Engl J Med 2012), enhancing the page with a scholarly reference.
    Difference
    0.6%
    Check dated 2025-10-12T14:49:54.000Z thumbnail image
  4. Check
    26 days ago
    Change Detected
    Summary
    The page now includes a general government-operating status notice and a new version tag (v3.2.0), while two specific article references about anti-PD-L1 and pembrolizumab were removed.
    Difference
    4%
    Check dated 2025-10-05T10:29:40.000Z thumbnail image
  5. Check
    33 days ago
    Change Detected
    Summary
    Added a key citation for a cancer immunotherapy study and updated the revision to v3.1.0; removed the older revision v3.0.2.
    Difference
    0.7%
    Check dated 2025-09-28T03:21:13.000Z thumbnail image
  6. Check
    41 days ago
    Change Detected
    Summary
    Replace a high-profile anti-PD-L1 cancer study reference with a randomized preoperative chemotherapy plus surgery trial for non-small-cell lung cancer; overall impact shifts content focus from immunotherapy to perioperative chemotherapy in lung cancer.
    Difference
    4%
    Check dated 2025-09-20T22:10:54.000Z thumbnail image
  7. Check
    48 days ago
    Change Detected
    Summary
    Version updated to v3.0.2, replacing v3.0.1; the old NSCLC trial reference and the Back to Top element were removed, with no substantive core-content changes.
    Difference
    1%
    Check dated 2025-09-13T17:42:00.000Z thumbnail image

Stay in the know with updates to Adjuvant Pembrolizumab in N2+ NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Adjuvant Pembrolizumab in N2+ NSCLC Clinical Trial page.